DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Azopt (Brinzolamide) - Summary

 
 



AZOPT SUMMARY

AZOPT
(brinzolamide ophthalmic suspension) 1%

AZOPT® (brinzolamide ophthalmic suspension) 1% contains a carbonic anhydrase inhibitor formulated for multidose topical ophthalmic use.

AZOPT® (brinzolamide ophthalmic suspension) 1% is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.


See all Azopt indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Azopt (Brinzolamide)

Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.

[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol]. [2011.05]
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol... CONCLUSIONS: Both fixed combinations were similarly effective in reducing intraocular pressure and ocular pulse amplitude. Adverse effects related to both treatments were mild and well-tolerated, though itching occurred most frequently in the eyes treated with dorzolamide/timolol. Copyright (c) 2011 Sociedad Espanola de Oftalmologia. Published by Elsevier Espana. All rights reserved.

Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. [2010.08]
PURPOSE: This study aims to identify progression factors in patients with primary open-angle glaucoma (POAG), including the effects of treatment with dorzolamide 2% or brinzolamide 1%, each added to timolol 0.5%... CONCLUSIONS: Progression increased with lower DBP, lower MAP, antihypertensive medication, lower EDV in the OA and SPCA, and higher RI in the OA and SPCA. The risk for progression in patients treated with DT was half that in patients treated with BT.

Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]
OBJECTIVE: To compare the efficacy of brimonidine, dorzolamide, and brinzolamide in reducing intraocular pressure (IOP) when used as adjunctive therapy to a prostaglandin analog (PGA)... CONCLUSIONS: The addition of brimonidine to a PGA provided greater IOP lowering than the addition of either dorzolamide or brinzolamide. Further studies are needed to evaluate the relative long-term efficacy and tolerability of these medications as adjunctive therapy to a PGA. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. [2009.06]
PURPOSE: To compare the effect on the retrobulbar hemodynamics and intraocular pressure (IOP) of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5% in patients with primary open-angle glaucoma (POAG)... CONCLUSIONS: Our results suggest augmented retrobulbar blood flow after 5 years of treatment with dorzolamide but not with brinzolamide, each added to timolol, in POAG patients.

more studies >>

Clinical Trials Related to Azopt (Brinzolamide)

Efficacy and Safety of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination BID vs. Brinzolamide 1% BID Plus Brimonidine 0.2% BID [Recruiting]
A multi-center, double-masked, randomized parallel group efficacy and safety study of brinzolamide 1% /brimonidine 0. 2% fixed combination compared to brinzolamide 1% plus brimonidine 0. 2% in patients with open-angle glaucoma or ocular hypertension.

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension [Recruiting]
A multi-center, double-masked, randomized parallel group efficacy and safety study of brinzolamide 1% /brimonidine 0. 2% fixed combination compared to brinzolamide 1% and to brimonidine 0. 2% in patients with open-angle glaucoma or ocular hypertension.

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% [Recruiting]

Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome [Recruiting]
This study is a prospective, single crossover, double-masked, controlled clinical trial that will use topical brinzolamide (Azopt)ophthalmic medication to try to improve the nystagmus and visual consequences of nystagmus in patients with infantile nystagmus syndrome (INS). Subjects will undergo a clinical exam, questionnaire and eye movement recordings on day 1 and then receive either topical Azopt or placebo three times a day in both eyes for days 2,3 and 4 followed on the morning of day 5 by a repeat clinical exam, questionnaire and eye movement recordings. After at least one week, this protocol is repeated with the crossover regimen being taken by the subject. One week after all medications are discontinued, another clinical exam is done before study discharge. The hypothesis is that nystagmus and associated visual symptoms will be improved while on the Azopt compared to the placebo. There will be a total of 5 visits over a 1-2 month period.

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs [Completed]
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.

more trials >>

Reports of Suspected Azopt (Brinzolamide) Side Effects

Dyspnoea (8)Intraocular Pressure Increased (6)Depression (5)Deafness Transitory (5)Vision Blurred (5)Drug Ineffective (4)Sudden Cardiac Death (4)Deafness (4)Drug Hypersensitivity (4)Diaphragmatic Paralysis (3)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Azopt has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Azopt review by 49 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   glaucoma
Dosage & duration:   1 drop (dosage frequency: 2x daily) for the period of 5 years
Other conditions:   none
Other drugs taken:   betagan, alphagan
  
Reported Results
Benefits:   Although this is not available in generic, I am using the generic versions of alphagan and betagan in conjunction with this drug. Each drug was used independently to determine side effects before they were combined for treatment. (This was a many visit process! But the results have made it was worth it) This combination lowered my intraoccular pressure to the point that it was not necessary to have surgery - my next step since other combinations did not work.
Side effects:   Occasional burning when put into already irritated eyes.
Comments:   In conjunction with the above mentioned drops, I have had consistently lowered pressure with no side effects.

See all Azopt reviews / ratings >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012